Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis

Xie, Han; Zhang, Yuan; Zhu, Zunyi; Wei, Jingxuan; Ainiwaer, Gulinigeer; Ge, Weihong

doi:10.1007/s40744-023-00636-z

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-responders had higher plasma levels of galectin-1, galectin-3, and CD44 than responders after imrecoxib treatment. 36 …”

Section: Methodsmentioning

confidence: 99%

“…Non-responders had higher plasma levels of galectin-1, galectin-3, and CD44 than responders after imrecoxib treatment. 36 In a prospective clinical trial including knee osteoarthritis patients on imrecoxib therapy for 4 weeks, Wu et al analyzed the plasma steady-state trough concentrations of imrecoxib and its two metabolites with anti-inflammatory activities similar to their parent drug[4'-hydroxyimrecoxib (M1), and 4'-carboxyimrecoxib (M2)]. The mean plasma steady-state trough concentrations of imrecoxib, M1 and M2 were 7.10, 9.49, and 50.91 μg/L, respectively.…”

Section: Biomarkers For Evaluating Early Efficacy Of Imrecoxibmentioning

confidence: 99%

See 1 more Smart Citation

Imrecoxib: Advances in Pharmacology and Therapeutics

Wang,

Zhu,

et al. 2024

DDDT

View full text Add to dashboard Cite

Imrecoxib, a cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug (NSAID), was discovered via the balanced inhibition strategy of COX-1/COX-2. It is indicated for the relief of painful symptoms of osteoarthritis. There have been some pharmacological and therapeutic advances since the approval of imrecoxib in 2011. However, an update review in this aspect is not yet available. Relevant literature until January 2024 was identified by search of PubMed, Web of science, Embase and CNKI. From the perspective of efficacy, imrecoxib provides relief of osteoarthritis symptoms, and potential off-label use for treatment of idiopathic pulmonary fibrosis, perioperative pain, hand-foot syndrome, axial spondyloarthritis, COVID-19, cartilage injury, and malignancies such as lung and colon cancer. From a safety point of view, imrecoxib showed adverse effects common to NSAIDs; however, it has lower incidence of new-onset hypertension than other types of selective COX-2 inhibitors, less gastrointestinal toxicities than non-selective NSAIDs, weaker risk of drug interaction than celecoxib, and more suitable for elderly patients due to balanced inhibition of COX-1/COX-2. From a pharmacoeconomic perspective, imrecoxib is more cost-effective than celecoxib and diclofenac for osteoarthritis patients. With the deepening of the disease pathophysiology study of osteoarthritis, new therapeutic schemes and pharmacological mechanisms are constantly discovered. In the field of osteoarthritis treatment, mechanisms other than the analgesic and anti-inflammatory effects of COX-2 inhibitors are also being explored. Taken together, imrecoxib is a moderate selective COX-2 inhibitor with some advantages, and there would be more clinical applications and research opportunities in the future.

show abstract

“…Non-responders had higher plasma levels of galectin-1, galectin-3, and CD44 than responders after imrecoxib treatment. 36 …”

Section: Methodsmentioning

confidence: 99%

Section: Biomarkers For Evaluating Early Efficacy Of Imrecoxibmentioning

confidence: 99%

Imrecoxib: Advances in Pharmacology and Therapeutics

Wang,

Zhu,

et al. 2024

DDDT

View full text Add to dashboard Cite

show abstract

Comparative Study on the Sperm Proteomes of Horses and Donkeys

Ren,

Wen,

et al. 2024

Animals

View full text Add to dashboard Cite

The reproductive performance of horse sperm and donkey sperm has been reported to differ. Sperm proteins play a crucial role in sperm viability and fertility. Although differences between species are known, no prior study has investigated disparities in the sperm proteome between horses and donkeys. Therefore, this study characterized and compared the sperm proteomes of horses and donkeys using 4D-DIA mass spectrometry technology. We identified 3436 proteins in horse sperm and 3404 proteins in donkey sperm. Of these, 3363 proteins were expressed in both horse and donkey sperm, with 73 proteins being specifically expressed in horse sperm, and 41 in donkey sperm. According to data analysis, donkeys exhibited a greater percentage of motility and progressive movement in straight-line sperm than horses, as well as lower percentages of static and slow sperm than horses. Joint analysis of the results from the horse and donkey sperm proteomes and their CEROS II-read parameters demonstrated a possible association between sperm proteins and their sperm viability patterns. These findings suggest that there are discrepancies in the expression levels and protein compositions of horse and donkey sperm and that certain specific proteins may be responsible for the differences in performance between these two species.

show abstract

Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis

Cited by 2 publications

References 37 publications

Imrecoxib: Advances in Pharmacology and Therapeutics

Imrecoxib: Advances in Pharmacology and Therapeutics

Comparative Study on the Sperm Proteomes of Horses and Donkeys

Contact Info

Product

Resources

About